- Clearmind Medicine Inc. reported a **net loss** of **$1,313,592** for the three months ended **July 31, 2025**, and **$3,169,141** for the nine months ended **July 31, 2025**.  **[1892500_0001213900-25-086821_ea025617001ex99-2_clearmind.htm:4]** 
- As of **July 31, 2025**, the company held **$3,495,338** in cash and cash equivalents and had **$918,215** in working capital.  **[1892500_0001213900-25-086821_ea025617001ex99-2_clearmind.htm:6]** 
- The company initiated its **Phase I/IIa clinical trial** for CMND-100 in Alcohol Use Disorder (AUD) in Israel in **March 2025** and in the U.S. in **April 2025**, with the first patient dosed in **June 2025** at Yale School of Medicine.  **[1892500_0001213900-25-086821_ea025617001ex99-2_clearmind.htm:2]** 
- On **December 16, 2025**, Clearmind announced signing a non-binding term sheet with Dr. Glitter Pty Ltd for the development and commercialization of a MEAI-based alcohol substitute.  **[1892500_0001213900-25-086821_ea025617001ex99-2_clearmind.htm:2]** 
- The company anticipates its current cash and cash equivalents will provide sufficient liquidity for at least **twelve months**, though additional financing may be required to advance all its programs.  **[1892500_0001213900-25-086821_ea025617001ex99-2_clearmind.htm:6]**

Clearmind Medicine (CMND)